US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)

Trial Identifier:	D3143R00004
Sponsor:	AstraZeneca
Collaborator:	IQVIA
NCTID::	NCT04125290
Start Date:	December 2019
Primary Completion Date:	December 2023
Study Completion Date:	December 2023
Condition:	Leukemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United States of America, CO	Pueblo, CO, United States of America, 81008
United States of America, MO	Bridgeton, MO, United States of America, 63044

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.